BrainSee

A product of Darmiyan

BrainSee Is A
Medical Device

BrainSee is: clinical software designed to be used as a medical device in the clinical setting to aid in the prognosis of patients who have amnestic mild cognitive impairment (aMCI).

BrainSee is: A novel AI algorithm running in the cloud that processes patient medical data (details below) and gives a score (between 0 and 100%) that reflects the likelihood of progression from mild cognitive impairment to Alzheimer’s dementia within 5 years.

Novel technology behind BrainSee

We have developed the first Virtual Microscope of the brain, patent protected, based on 40 years of cutting edge neuroscience research, AI, and “collection + curation” of thousands of retrospective, longitudinal patient data. BrainSee is the first application of our Virtual Microscope. It is an AI-powered software that processes each patient’s brain MRI scan, pulling critical information that is physiologically relevant to the brain tissue degeneration, and combines it with basic demographics and baseline cognitive information to provide a whole brain score to the physician. Such a highly informative, yet simple whole brain score is on a scale of 0 to 100% and captures personalized brain wellness and prognosis that can be used by doctors to choose the best course of treatment or interventions for patients. 

Why use BrainSee instead of PET or CSF biomarkers?

Users: Medical Doctors

Who evaluate patients with mild cognitive impairment such as geriatricians, neurologists, family physicians, primary care physicians, psychiatrists.

Target patients: Mild cognitive impairment

have memory concerns today.

may or may not have Alzheimer’s disease.

may or may not progress to Alzheimer’s dementia in the future. They can improve or stay stable – those who do not have Alzheimer’s disease.

AdobeStock_226212015 (1)-min

Benefits

  • For lower-risk patients (BrainSee score < 50%): reassurance is provided without having to go through invasive tests such as CSF lumbar puncture biomarker measurements, or amyloid PET (radiotracer injection, radiation exposure, high cost, low accessibility, low PPV). Repeating the test annually is possible if patient & doctor request for additional and continual reassurance
  • For higher-risk patients (BrainSee score > 50%): enabling early interventions that can postpone the onset of symptoms (medications, lifestyle modifications), and early life and care planning. Repeating the test quarterly is possible if patient & doctor request for additional and continual evaluation
  • For doctors: enables a data driven approach to diagnostic/ prognostic decision making; increase efficiency of their workflow; & facilitates a quantitative assessment about the disease status with patients and family members
AdobeStock_91227491-min

Input & output

Input: Brain MRI (standard, no contrast agent, no radiation exposure), baseline cognitive assessment, basic demographics (age, gender). Note: All input requirements are a part of current medical workup for mild cognitive impairment patients.

Output: an automated AI generated report that provides a BrainSee score and how to interpret it.

FDA status

Breakthrough designated (May 28, 2021).

Beta testing by selected doctors (contact us if you are interested).

Expected approval and market entry: Q1 2023.

AdobeStock_206037348 (1)-min

BrainSee Stories

Ready to explore BrainSee?

For more details visit us on twitter